Core Insights - The biopharmaceutical company is planning to introduce two cancer therapies and an additional HIV treatment option within this year [1] Company Developments - The company is focusing on expanding its product offerings in the oncology and HIV treatment sectors [1]

Core Insights - DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the AAAAI 2026 Annual Meeting in Philadelphia from February 27 to March 2, 2026 [1] - The company will host a product theater featuring allergists discussing the potential of epicutaneous immunotherapy (EPIT) in food allergy treatment and the impact of early intervention [2] Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which can cause severe reactions including anaphylaxis [4] - The VIASKIN® patch aims to introduce microgram amounts of biologically active compounds to the immune system through intact skin, representing a non-invasive treatment approach [4] Event Details - The oral abstract presentation titled "VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age" will take place on February 28, 2026 [3][6] - The product theater session titled "Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment" will also occur on February 28, 2026 [3][6] - DBV will exhibit at booth 1527 at the AAAAI exhibit hall to provide more information about epicutaneous immunotherapy and the VIASKIN® Peanut Patch [3]

Core Viewpoint - Avadel Pharmaceuticals plc has received approval from the Irish High Court for a scheme of arrangement that will allow Alkermes plc to acquire all issued shares of Avadel, marking a significant step in the Proposed Transaction [1][2]. Company Overview - Avadel Pharmaceuticals plc is a biopharmaceutical company focused on innovative medication solutions, with its commercial product LUMRYZ™ being the first and only once-at-bedtime oxybate approved for treating narcolepsy in patients aged 7 and older [5]. Proposed Transaction Details - The Proposed Transaction involves Alkermes acquiring the entire issued and to be issued ordinary share capital of Avadel [1]. - The completion of the Proposed Transaction is contingent upon the delivery of a copy of the Court Order sanctioning the Scheme to the Registrar of Companies [2]. - The Court Order is expected to be processed by February 11, 2026, with the Scheme taking effect on February 12, 2026, leading to the last trading day of Avadel Shares on Nasdaq being February 11, 2026 [3].

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to ...

Core Insights - NurExone Biologic Inc. announced positive results from an independent proteomic analysis that supports its Chemistry, Manufacturing and Controls (CMC) readiness, which is crucial for potential Investigational New Drug (IND) application and subsequent human clinical trials [1][4] Manufacturing Consistency - The analysis demonstrated batch-to-batch consistency in NurExone's exosome production, with four independent batches showing a highly consistent protein "fingerprint," indicating robustness and reproducibility in the manufacturing process [2][4] Therapeutic Potential - The evaluation revealed several therapeutically potential proteins in NurExone's exosomes that were not present in commercial reference samples, highlighting a distinct biological profile associated with inflammation control, cellular resilience, and nerve repair support [3][4] Development Focus - NurExone's near-term development strategy includes milestones aimed at reducing technical and regulatory risks, alongside establishing small-scale clinical manufacturing capabilities in Israel to transition from research-scale to clinical-grade production [4][11] Engagement with Strategic Communications - The company has reengaged Russo Partners LLC for public and investor relations services for an additional 3-to-6-month term, with a monthly fee of US$15,000, subject to TSX Venture Exchange approval [8][9] Company Overview - NurExone is focused on developing regenerative exosome-based therapies for central nervous system injuries, with its lead product, ExoPTEN, showing strong preclinical data for treating acute spinal cord and optic nerve injuries, which are significant market opportunities [11]

Core Insights - Incyte reported strong financial performance for 2025, with total revenue of $5.14 billion, up 21%, and core product sales excluding Jakafi increasing by 53% to $1.26 billion, driven by OPZELURA, Niktimvo, and MONJUVI [4][2][3] Financial Performance - Jakafi sales reached $3.093 billion in 2025, reflecting an 11% increase year-over-year, with fourth quarter sales of $828 million, up 7% [1][4] - Total revenue for the fourth quarter was $1.51 billion, a 28% increase compared to the previous year, with net product sales of $1.22 billion, up 20% [2] - Management expects 2026 revenue guidance of $4.77 billion to $4.94 billion, with core business sales excluding Jakafi projected to be $1.57 billion to $1.69 billion, indicating approximately 30% growth at the midpoint [10] Product Performance - OPZELURA achieved fourth quarter net sales of $207 million, up 28%, and full-year net sales of $678 million, up 33%, driven by increased penetration in U.S. atopic dermatitis and vitiligo [5][6] - Hematology and oncology products generated fourth quarter net sales of $187 million, up 121%, and full-year sales of $583 million, up 83%, supported by Niktimvo, MONJUVI, and ZYNYZ [6] Pipeline and Development - The company is accelerating late-stage development with 14 pivotal trials across seven assets expected by the end of 2026, including anticipated FDA acceptance for povorcitinib in hidradenitis suppurativa in Q1 2026 [3][9] - Recent approvals include MONJUVI for follicular lymphoma and ZYNYZ for squamous cell anal carcinoma, with ongoing submissions for Jakafi XR and OPZELURA [8] Strategic Focus - Management emphasized 2026 as an "inflection point," focusing on execution across product launches and multiple Phase III programs, aiming to create a strong growth trajectory post-2029 [13] - The company plans to enhance formulary access for Jakafi XR, targeting a 10% to 30% conversion rate over time [5]

Group 1 - Pfizer Inc. announced that the U.S. FDA accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI, expanding its indication to treat hemophilia A or B patients aged 6 years and older with inhibitors, and pediatric patients with hemophilia A or B without inhibitors [1][2] - The FDA set a Prescription Drug User Fee Act action date for HYMPAVZI in Q2 2026, which, if approved, would offer a once-weekly subcutaneous injection for bleed protection without the need for routine lab monitoring [2] - Pfizer launched the TrumpRx program to make over 30 innovative medicines more accessible and affordable for Americans, providing significant discounts off list prices as part of a broader agreement with the U.S. government [3] Group 2 - Pfizer Inc. is a global biopharmaceutical company focused on the development, manufacturing, and marketing of biopharmaceutical products, aiming to advance wellness and treatment in developing and emerging markets [4]

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified class period, alleging misleading statements regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Ultragenyx shares from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint claims that Ultragenyx misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a decline of over 42% in a single day [3]. Group 3: Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2].

Core Insights - Stonegate Capital Partners has initiated coverage on AB Science S.A., focusing on its late-stage biotech asset, masitinib, which is an oral, selective tyrosine kinase inhibitor aimed at modulating maladaptive neuroinflammation [1] Company Overview - AB Science is advancing masitinib as an add-on therapy for conditions such as ALS (Amyotrophic Lateral Sclerosis), progressive MS (Multiple Sclerosis), and Alzheimer's Disease (AD) [1] - The company is also developing AB8939 for Acute Myeloid Leukemia (AML), indicating a diverse pipeline [1] Clinical Development - The ALS program is supported by prior Phase 2b/3 data, enhancing confidence in its efficacy [6] - For progressive MS, a Phase 3 trial has been authorized in the US and 12 EU countries, with approximately 94 sites initiating the study [6] - Financing for these trials is supported by grants, indicating a solid financial backing for ongoing research [6]

Core Insights - Sanofi has completed the acquisition of Dynavax Technologies Corporation, enhancing its portfolio in adult immunization with Dynavax's hepatitis B vaccine HEPLISAV-B and shingles vaccine candidate Z-1018 [1][2] Acquisition Details - The tender offer for Dynavax's common stock expired on February 9, 2026, and all conditions were satisfied, leading to Sanofi's acceptance of the shares [3] - The acquisition was finalized through a merger, with Dynavax becoming a wholly owned subsidiary of Sanofi, and shares not tendered in the offer will receive $15.50 per share in cash [4] Strategic Implications - This acquisition strengthens Sanofi's commercial reach and development capabilities in the vaccine market, positioning the company for growth in adult immunization [2]